Explore more publications!
Vanuatu Health Times
Submit Press Release

Vanuatu Health Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Vanuatu Health Times.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on November 9, 2025

Avance Clinical, ‘신장 및 심대사 질환 우수 센터’ 설립하며 환자 모집 최적화 통해 임상시험 성공률 제고에 박차
November 9, 2025

Avance Clinical, ‘신장 및 심대사 질환 우수 센터’ 설립하며 환자 모집 최적화 통해 임상시험 성공률 제고에 박차

Indeterminate GlobeNewswire
Avance Clinical 宣布成立肾脏与心血管代谢卓越中心，优化患者招募以提升研究成功率
November 9, 2025

Avance Clinical 宣布成立肾脏与心血管代谢卓越中心，优化患者招募以提升研究成功率

Indeterminate GlobeNewswire
Avance Clinical 成立腎臟與心血管代謝卓越中心，優化患者招募流程以提升研究成功率
November 9, 2025

Avance Clinical 成立腎臟與心血管代謝卓越中心，優化患者招募流程以提升研究成功率

Indeterminate GlobeNewswire
AVITA Medical to Host Investor Webinar Briefing
November 9, 2025

AVITA Medical to Host Investor Webinar Briefing

Indeterminate GlobeNewswire
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
November 9, 2025

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

Indeterminate GlobeNewswire
RadNet Reports Third Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA¹ and Revises Upwards 2025 Financial Guidance Ranges
November 9, 2025

RadNet Reports Third Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA¹ and Revises Upwards 2025 Financial Guidance Ranges

Indeterminate GlobeNewswire
AHA 2025: Late-Breaking Data Reinforce the Prognostic Power of AI-Driven Heartflow Plaque Analysis as the Most Clinically Validated Framework for Coronary Risk Stratification
November 9, 2025

AHA 2025: Late-Breaking Data Reinforce the Prognostic Power of AI-Driven Heartflow Plaque Analysis as the Most Clinically Validated Framework for Coronary Risk Stratification

Indeterminate GlobeNewswire
Intermountain Health Research: Targeted Vitamin D3 Supplementation Cuts Risk of Heart Attack Patients Having a Second Heart Attack in Half
November 9, 2025

Intermountain Health Research: Targeted Vitamin D3 Supplementation Cuts Risk of Heart Attack Patients Having a Second Heart Attack in Half

Indeterminate GlobeNewswire
George Medicines presents long-term efficacy and safety data for single pill triple combination therapy for hypertension at American Heart Association’s Scientific Sessions 2025
November 9, 2025

George Medicines presents long-term efficacy and safety data for single pill triple combination therapy for hypertension at American Heart Association’s Scientific Sessions 2025

Indeterminate GlobeNewswire
Medera Presents Late-Breaking Data from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at American Heart Association Scientific Sessions 2025
November 9, 2025

Medera Presents Late-Breaking Data from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at American Heart Association Scientific Sessions 2025

Indeterminate GlobeNewswire
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025
November 9, 2025

Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025

Indeterminate GlobeNewswire

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions